NASDAQ OMX

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

Dela

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study.

Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performance, quality of life, and survival in patients with this disease."

The study will also assess overall and progression free survival as well as evaluate the relationship between treatment tolerance and patient functional status. Various secondary measures, including changes in lean body mass, weight stability and levels of systemic inflammation will also be monitored. Onivyde will be given intravenously with MABp1 and 5-fluorouraci l /folinic acid every two weeks until disease progression.

The prognosis for advanced pancreatic cancer remains poor despite decades of studies [1].  The 5-year survival has remained close to 5%, unchanged despite improvements in chemotherapeutics, surgical outcomes, and diagnostic techniques [1, 2].  Other than multi-agent cytotoxic therapy there have been no treatment advances for pancreatic cancer or its associated cachexia.

MABp1 was found to improve clusters of symptoms that included reduced pain, fatigue, improved appetite and increased lean body mass in advanced cancer patients. Patients that had these improvements were found to have less tumor progression, substantial reduced serious adverse events related to disease, and about a three-fold improvement in survival [3].

About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

  1. Li, D., et al.,  Pancreatic cancer.  Lancet, 2004.  363 (9414): p. 1049-57.
  2. Panagiotarakou, M., et al.,  Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care.  Jop, 2012.  13 (4): p. 342-4.
  3. Hickish T., et al.,  MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol. 2017 Feb;18(2):192-201.



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring23.11.2017 14:00Pressmeddelande

SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announces the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI). Crown Bioscience's clinically relevant models and DSI's HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research. Recently published work in the Journal of Endocrinological Investigation and Nature's Scientific Reports demonstrates the advantages of a new method using DSI's HD-XG implantable glucose device and Crown Bioscience's models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement

LeoVegas AB: Nomination committed appointed for LeoVegas ahead of 2018 Annual General Meeting23.11.2017 11:50Pressmeddelande

In accordance with the principles for appointment of a nomination committee of LeoVegas AB (publ) ("the Company" or "LeoVegas") that were adopted by the Annual General Meeting on 17 May 2017, the Nomination Committee shall consist of four members appointed by the three largest shareholders as at 30 September 2017, together with the Chairman of the Board. Based on the above, the Nomination Committee ahead of the 2018 Annual General Meeting has been determined to consist of the following persons, who represent approximately 23% of the number of shares and votes in the Company as per 30 September 2017: Anders Fast, Nomination Committee chair, representing Gustaf Hagman Joachim Spetz, representing Swedbank Robur Fonder Dan-Alp Lindberg, representing Robin Ramm-Ericson Mårten Forste, Chairman of the Board The No

LeoVegas AB: Valberedning utsedd i LeoVegas inför årsstämma 201823.11.2017 11:50Pressmeddelande

Enligt de principer för valberedning i LeoVegas AB (publ) ("Bolaget" eller "LeoVegas") som antogs på årsstämman den 17 maj 2017 ska valberedningen bestå av fyra ledamöter utsedda av de tre största aktieägarna per den 30 september 2017, jämte styrelsens ordförande. Baserat på ovanstående har valberedningen inför årsstämman 2018 fastställts till att bestå av följande personer som tillsammans representerar cirka 23 procent av antalet aktier och röster i Bolaget per den 30 september 2017: Anders Fast, valberedningens ordförande och utsedd av Gustaf Hagman Joachim Spetz, utsedd av Swedbank Robur Fonder Dan-Alp Lindberg utsedd Robin Ramm-Ericson Mårten Forste, styrelseordförande Valberedningens förslag kommer att presenteras i kallelsen till årsstämman 2018 samt på bolagets hemsida, www.leovegasgroup.com.

Hemcheck Sweden AB: Viktigt patent beviljat av PRV23.11.2017 09:00Pressmeddelande

PRESSMEDDELANDE   Viktigt patent beviljas av PRV PRV, det svenska patent och registreringsverket, meddelar att HemChecks patentansökan gällande bolagets blodseparationsteknik kommer att beviljas för Sverige den 19 december 2017. Patentets publiceringsnummer kommer att bli 539853. -För HemCheck är patentet strategiskt mycket viktigt, eftersom det innefattar vår teknik för blodseparation. Det skyddar den teknik som gör att en ej definierad blodvolym kan användas i vårt engångstest och det är just det som gör vårt hemolystest så unikt, enkelt och användarvänligt - och dessutom mycket snabbt. I kombination med övriga patent har vi nu ett mycket bra skydd för den metod som HemChecks affärsidé i grunden bygger på, säger vd Annelie Brolinson i en kommentar. En internationell patentansökan har lämnats in för att söka skydd på övriga viktiga marknader.  För ytterligare information, kontakta: Hemcheck Sweden AB

BDA partners with government to attract cryptocurrency23.11.2017 06:25Pressmeddelande

HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- The Bermuda Business Development Agency (BDA) will take a lead role in an initiative launched by the Bermuda government today to accelerate the establishment and growth of digital currency business on the island. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/457f43b9-d7bb-48f1-83e2-b856b33ebacc At a press conference held by Premier the Hon David Burt and National Security Minister the Hon Wayne Caines, the government announced the formation of a task force comprising two teams to advance Bermuda's regulatory environment as a destination for utility tokens, tokenised securities, cryptocurrencies, and coin offerings. BDA Consultant for Emerging Technologies John Narraway was named as chair of the Blockchain Business Development Working Group, while BDA Board member Lydia Dickens will chair the Blockchain Legal and Regulatory Working Group, of which

VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller22.11.2017 11:39Pressmeddelande

The sale will be the most significant philanthropic auction ever presented LONDON, Nov. 22, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, announces today its worldwide sponsorship of the exhibition and tour of The Collection of Peggy and David Rockefeller, the most significant auction entirely dedicated to raising funds for philanthropic causes.  The sale, consisting of numerous categories, will be conducted by Christie's, the world's leading art business, and will include a highlights exhibition tour in Hong Kong, London, Los Angeles and New York. Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c78fdce7-7651-42a8-a621-14088da2cc86 http://www.globenewswire.com/NewsRoom/AttachmentNg/33af2489-a9a8-4bbe-b5f7-78e4c1f29ca2 http://www.globenewswire.com/NewsRoom/AttachmentNg/a16c2

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum